Cancers, Vol. 12, Pages 1929: Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems

Cancers, Vol. 12, Pages 1929: Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems Cancers doi: 10.3390/cancers12071929 Authors: Ranjit Manchanda Li Sun Shreeya Patel Olivia Evans Janneke Wilschut Ana Carolina De Freitas Lopes Faiza Gaba Adam Brentnall Stephen Duffy Bin Cui Patricia Coelho De Soarez Zakir Husain John Hopper Zia Sadique Asima Mukhopadhyay Li Yang Johannes Berkhof Rosa Legood Clinical criteria/Family history-based BRCA testing misses a large proportion of BRCA carriers who can benefit from screening/prevention. We estimate the cost-effectiveness of population-based BRCA testing in general population women across different countries/health systems. A Markov model comparing the lifetime costs and effects of BRCA1/BRCA2 testing all general population women ≥30 years compared with clinical criteria/FH-based testing. Separate analyses are undertaken for the UK/USA/Netherlands (high-income countries/HIC), China/Brazil (upper–middle income countries/UMIC) and India (low–middle income countries/LMIC) using both health system/payer and societal perspectives. BRCA carriers undergo appropriate screening/prevention interventions to reduce breast cancer (BC) and ovarian cancer (OC) risk. Outcomes include OC, BC, and additional heart disease deaths and incremental cost-effectiveness ratio (ICER)/quality-adjusted life year (QALY). Proba...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research